Tweet
Hum Vaccin Immunother
. 2022 Jun 20;2083428.
doi: 10.1080/21645515.2022.2083428. Online ahead of print.
Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice
Abenaya Muralidharan 1 2 , Caroline Gravel 3 , Greg Harris 4 , Anwar M Hashem 5 6 , Wanyue Zhang 1 3 , David Safronetz 7 , Gary Van Domselaar 7 , Florian Krammer 2 , Simon Sauve 3 , Michael Rosu-Myles 1 3 , Lisheng Wang 1 , Wangxue Chen 4 , Xuguang Li 1 3
Affiliations
- PMID: 35724343
- DOI: 10.1080/21645515.2022.2083428
Abstract
Influenza is a major public health concern causing millions of hospitalizations every year. The current vaccines need annual updating based on prediction of likely strains in the upcoming season. However, mismatches between vaccines and the actual circulating viruses can occur, reducing vaccine effectiveness significantly because of the remarkably high rate of mutation in the viral glycoprotein, hemagglutinin (HA). Clearly, it would be of great interest to determine the potential role of universally conserved epitopes in inducing protective immunity. Here, an antibody against the 14-aa fusion peptide sequence at the N-terminus of the HA2 subunit (Uni-1) was investigated for its ability to elicit antibody-dependent cellular cytotoxicity (ADCC) in vitro and cross-protection against lethal infection in animals. Uni-1, known to neutralize influenza type A (IAV) in vitro, was found to induce strong ADCC against diverse influenza viruses, including human and avian IAVs and both lineages of type B (IBV). The ADCC effects against human IAVs by Uni-1 was comparable to ADCC induced by well-characterized antibodies, F10 and FI6V3. Importantly, mice treated with Uni-1 were protected against lethal challenge of IAV and IBV. These results revealed the versatile effector functions of this universal antibody against markedly diverse strains of both IAV and IBV.
Keywords: Influenza; Uni-1; antibody-dependent cellular cytotoxicity (ADCC); cross-protection; universal antibody.